(Q46158177)

20 December 2017

http://europepmc.org/abstract/MED/19151776

title

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma (English)

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

author

Samantha Pozzi

8

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

Tanyel Kiziltepe

11

object named as

T Kiziltepe

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

author name string

N Raje

1

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

T Hideshima

2

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

S Mukherjee

3

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

M Raab

4

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

S Vallet

5

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

S Chhetri

6

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

D Cirstea

7

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

C Mitsiades

9

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

M Rooney

10

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

K Podar

12

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

Y Okawa

13

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

H Ikeda

14

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

R Carrasco

15

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

P G Richardson

16

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

D Chauhan

17

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

N C Munshi

18

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

S Sharma

19

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

H Parikh

20

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

B Chabner

21

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

D Scadden

22

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

K C Anderson

23

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

publication date

8 January 2009

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

published in

Leukemia

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

volume

23

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

issue

5

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

page(s)

961-970

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

cites work

Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

Cell cycle progression without cyclin D-CDK4 and cyclin D-CDK6 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

Flavopiridol, an inhibitor of transcription: implications, problems and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

Advances in biology of multiple myeloma: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Thalidomide--a revival story

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Evolving role of stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Molecular pathogenesis and a consequent classification of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Using genomics to identify high-risk myeloma after autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Early genetic events provide the basis for a clinical classification of multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Isolation and characterization of human multiple myeloma cell enriched populations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Cyclin-dependent kinase inhibitors for treating cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Cell-cycle control of plasma cell differentiation and tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Cell-cycle targeted therapies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

CDK inhibitors in cancer therapy: what is next?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Relevance of cyclin D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Mouse development and cell proliferation in the absence of D-cyclins.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.378

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.378

1 reference

20 December 2017

http://europepmc.org/abstract/MED/19151776

Dimensions Publication ID

1009878262

0 references

1 reference

20 December 2017